We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Physiomics Plc | LSE:PYC | London | Ordinary Share | GB00BDR6W943 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.50 | 1.40 | 1.60 | 1.50 | 1.50 | 1.50 | 195,426 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 597k | -477k | -0.0035 | -4.29 | 2.03M |
Date | Subject | Author | Discuss |
---|---|---|---|
15/6/2018 11:16 | Any idea how many placing shares left? Almost at placing price.Time to buy? | flesh | |
14/6/2018 13:13 | Where are the contracts Where is the grant | spacedust | |
14/6/2018 13:12 | They are trying everything but nothing will work. This share is destroyed. Rinse repeat. Consolidate. Destroy. | spacedust | |
14/6/2018 08:26 | An RNS for an updated website? Really?! | richardc77 | |
12/6/2018 00:52 | I own spacedust mining* | spacedust | |
12/6/2018 00:51 | Btw let me remind you that i won Spacedust Mining. I am in the same field as Glencore and BHP. So this obviously means that my company will be worth billions billions purely because inna in the same fi3ld right? | spacedust | |
11/6/2018 18:32 | How does a company that only models dosage predictions for one type of disease be in compete with 800+m companies that actually design drugs like Grail and deepmind? Answer. It doesn't, it can't, it doesn't do remotely the same thing. Those companies are like modern paint companies developing the latest tech in coverings, and pyc have a computer system to work out how much red to put in white to make pink. Not that the paint companies don't have that facility already... | davevt | |
11/6/2018 17:16 | Watch this spacedust!!! | spacedust | |
11/6/2018 16:38 | They've had that website for years. Pharmas and Biotechs wouldn't care one jot. As I've said repeatedly they are now on a whole different level competing with/collaborating with likes of DeepMind and GRAIL which come from IT/Tech background not Pharma/Bio background. So NOW the website becomes an issue. Watch this space indeed ! | the stigologist | |
11/6/2018 16:28 | CLIENTS create revenue. SHAREHOLDERS do not. LOL!!!!! | fqr714bhp | |
11/6/2018 16:11 | Updated Website Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that following feedback from clients and shareholders it has today updated its website at hxxp://www.physiomic The website address for the purposes of AIM Rule 26 remains unchanged. In its recent placing announcement of the 23 May 2018, the Company stated its intention to improve its marketing approach, and the launch of the new site is a small but important step towards executing this goal. Features of the upgraded site include: -- Fresher, cleaner more modern look and feel -- Clearer, simpler descriptions of our services and technologies -- Easier navigation and viewing on small personal devices -- Addition of mailing list functionality so investors and clients can sign up to receive news as it happens -- Enhancement of Corporate Governance section to comply with forthcoming requirements for AIM quoted companies -- Updates to ensure compliance with GDPR Further features and functionality will be added going forwards so please watch this space! | the stigologist | |
11/6/2018 16:08 | Prediction 40p+ before end of 2018 | fqr714bhp | |
11/6/2018 16:05 | At the moment you can't even buy 200000 of these. LOL!!!!!! | fqr714bhp | |
11/6/2018 15:36 | then 3200% boom! Hopefully, lots of "Joe Mug" shorters, without guaranteed stop losses, when the share price gaps up. Any bears wanting to put their names to 2p next before 6p? Cut & Paste 6p predictors howdlep 2p predictors | howdlep | |
11/6/2018 15:04 | Drip drip destroy Rinse repeat take wages. Sell holdings Drip drip destroy | spacedust | |
11/6/2018 14:25 | Dr Chassagnole's beneficial holding remains unchanged at 417,008 ordinary shares (equivalent to 0.71% of the currently issued share capital). Stig a advfn poster has 4 times more holdings than the director. Disgrace | spacedust | |
11/6/2018 14:21 | What nominee accounts? They must have mug punters. The only thing that will increase the share price with a sustained gradual move up is director buys or hedge funds taking positions. Look at ADT the director increased his holding to almost 20% and is continually buying. Look at TLY lots of hedge funds and directors. Both are aim shares with millions of pounds of revenue. Pyc is a milking cow machine that's it. Still no sign of any more contracts since the last one | spacedust | |
11/6/2018 13:09 | Physiomics web page has been updated, also shareholders holding updated. Peel Hunt increased holdings from 3 million to over 5 million. | myamay16 | |
10/6/2018 21:23 | PWhite73, You state "that the company can only raise money through the markets by selling shares to mug punters at increasingly lower prices." Once again that is simply not true. Why, because it is a FACT, as per the placing RNS dated 23 May, that "the placing price of 4p per share reflects a 60% premium to the price at which the Company last raised money in September 2016." Stocks on AIM have different degrees of liquidity, based on their free float. However, there are opportunities to invest in companies based on their newsflow, access to funding and ultimate profitability. Risk is increased when companies are not yet profitible. However, these are also the times when the greatest returns can be made. The 3200% rise (intra day high) from 1p to 32p is testament to that. So ultimately, investing is about risk/reward. I asked you to state whether you thought PYC's share price would hit 2p before it hit 6p and you have have deliberately ignored the question. So let other investors judge our transparency. | howdlep |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions